Is there any Royal College guidance for the long-term use of GnRH analogues, i.e., more than 6 months, in endometriosis or uterine fibroids?

This review investigated the existence of specific Royal College guidance regarding the long-term use of GnRH analogues for more than six months in patients with endometriosis or uterine fibroids. The authors found no direct evidence of such formal guidance, noting instead that indirect sources advocate for careful management strategies to mitigate side effects. These strategies primarily include the use of add-back therapy to allow for extended treatment duration while maintaining patient safety and tolerability. Relevance to endometriosis: listed as one indication for GnRH antagonists, though the paper's main focus is uterine fibroids.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works